Reply to V. Fusco et al

Journal of Clinical Oncology

Volumn 29, Issue 17, 2011, Pages

  Stopeck, Alison T ^a   Lipton, Allan ^b   Body, Jean Jacques ^c   Steger, Guenther G ^d   Tonkin, Katia ^e   De Boer, Richard H ^f   Lichinitser, Mikhail ^g   Fujiwara, Yasuhiro ^h   Yardley, Denise A ⁱ   Viniegra, María ^j   Fan, Michelle ^k   Jiang, Qi ^k   Dansey, Roger ^k   Jun, Susie ^k   Braun, Ada ^k  

^a UNIVERSITY OF ARIZONA   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e CROSS CANCER INSTITUTE   (Canada)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

^g N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^h NATIONAL CANCER CENTER HOSPITAL   (Japan)

ⁱ SARAH CANNON RESEARCH INSTITUTE   (United States)

^j Servicio de Oncologia   (Argentina)

^k AMGEN INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; PAMIDRONIC ACID; ZOLEDRONIC ACID;

BONE METASTASIS; BREAST CANCER; DRUG EFFICACY; HUMAN; JAW OSTEONECROSIS; LETTER; PRIORITY JOURNAL;

EID: 79959235264     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.2203     Document Type: Letter

References (21)

1. Fusco V, Galassi C, Berruti A, et al: Osteonecrosis of jaw after zoledronic acid and denosumab treatment. J Clin Oncol 29:e521-e522, 2011
2. Aragon-Ching JB, Ning YM, Chen CC, et al: Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 27:221-226, 2009
3. Badros A, Weikel D, Salama A, et al: Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 24:945-952, 2006 (Pubitemid 46638849)
4. Bagan JV, Jimenez Y, Murillo J, et al: Jaw osteonecrosis associated with bisphosphonates: Multiple exposed areas and its relationship to teeth extractions - Study of 20 cases. Oral Oncol 42:327-329, 2006 (Pubitemid 43246766)
5. Durie BG, Katz M, Crowley J: Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99-102, 2005; discussion 99-102
6. Hoff AO, Toth BB, Altundag K, et al: Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 24:475s, 2006 (suppl; abstr 8528)
7. Jadu F, Lee L, Pharoah M, et al: A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 18:2015-2019, 2007 (Pubitemid 350286242)
8. Zervas K, Verrou E, Teleioudis Z, et al: Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 patients. Br J Haematol 134:620-623, 2006 (Pubitemid 44253605)
9. Dimopoulos MA, Kastritis E, Bamia C, et al: Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20:117-120, 2009
10. Ripamonti CI, Maniezzo M, Campa T, et al: Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates: The experience of the National Cancer Institute of Milan. Ann Oncol 20:137-145, 2009
11. Stopeck AT, Lipton A, Body JJ, et al: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 28:5132-5139, 2010
12. Fizazi K, Carducci M, Smith M, et al: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 377:813-822, 2011
13. Henry DH, Costa L, Goldwasser F, et al: Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125-1132, 2011
14. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65:369-376, 2007
15. Ruggiero SL, Dodson TB, Assael LA, et al: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws: 2009 update. J Oral Maxillofac Surg 67:2-12, 2009 (suppl 5)
16. Novartis Pharmaceuticals: Zometa (zoledronic acid) injection, concentrate for intravenous infusion [prescribing information]. East Hanover, NJ, Novartis Pharmaceuticals, 2009
17. Medical Dictionary for Regulatory Activities Maintenance and Support Services Organization: About MedDRA. http://www.meddramsso.com/public-about- meddra.asp
18. Bamias A, Kastritis E, Bamia C, et al: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 23:8580-8587, 2005 (Pubitemid 46211499)
19. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al: Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Haematologica 91:968-971, 2006 (Pubitemid 44023154)
20. Amgen: XGEVA (denosumab) injection, for subcutaneous use, [prescribing information]. Thousand Oaks, CA, Amgen, 2010
21. Novartis Pharmaceuticals: Aredia (pamidronate disodium) injection, for intravenous infusion [prescribing information]. East Hanover, NJ, Novartis Pharmaceuticals, 2008